TEVA logo

TEVA

Teva Pharmaceutical Industries Limited American Depositary Shares

$19.50
+$0.63(+3.31%)
40
Overall
--
Value
40
Tech
--
Quality
Market Cap
$21.43B
Volume
10.29M
52W Range
$12.47 - $22.80
Target Price
$23.75
Order:

Income Statement

MetricTrendChart
2015
Dec
2016
Dec
2017
Dec
2018
Dec
2019
Dec
2020
Dec
2021
Dec
2022
Dec
2023
Dec
2024
Dec
REVENUE
Total Revenue
$19.7B$21.9B$22.4B$18.3B$16.9B$16.7B$15.9B$14.9B$15.8B$16.5B
Total Revenue
$19.7B$21.9B$22.4B$18.3B$16.9B$16.7B$15.9B$14.9B$15.8B$16.5B
COST OF GOODS SOLD
Cost of Revenue
$-8.3B$10.0B$11.6B$10.0B$9.4B$8.9B$8.3B$8.0B$8.2B$8.5B
GROSS PROFIT
Gross Profit
$11.4B$11.9B$10.8B$8.3B$7.5B$7.7B$7.6B$7.0B$7.6B$8.1B
OPERATING EXPENSES
Operating Expenses
$8.0B$4.9B$1.3B$3.4B$1.5B$2.6B$2.9B$4.2B$4.4B$4.7B
Research & Development
$1.5B$2.1B$1.8B$1.2B$1.0B$997.0M$967.0M$838.0M$953.0M$998.0M
Research Expense
$1.5B$2.1B$1.8B$1.2B$1.0B$997.0M$967.0M$838.0M$953.0M$998.0M
Selling, General & Administrative
$4.7B$5.1B$5.0B$4.2B$3.8B$3.7B$3.5B$3.4B$3.5B$3.7B
Selling & Marketing Expenses
$3.5B$3.9B$3.7B$2.9B$2.6B$2.5B$2.4B$2.3B$2.3B$2.5B
General & Administrative Expenses
$1.2B$1.3B$1.3B$1.3B$1.2B$1.2B$1.1B$1.2B$1.2B$1.2B
Promotion & Advertising
$-297.0M$312.0M$318.0M$256.0M$213.0M$225.0M$246.0M$168.0M$162.0M$259.0M
Salaries & Wages
$1.8B$-2.3B$-5.6B$-1.8B$-3.2B$-2.0B$-1.5B------
Depreciation & Amortization
$-1.3B$1.5B$2.1B$676.0M$609.0M$537.0M$528.0M$576.0M$537.0M$471.0M
Depreciation & Amortization
$-1.3B$1.5B$2.1B$676.0M$609.0M$537.0M$528.0M$576.0M$537.0M$471.0M
Amortization
$-838.0M$44.4B$28.4B$1.1B$1.1B$21.6B$20.8B$18.4B$17.8B$15.7B
Other Operating Expenses
$-911.0M$-71.0M$-26.0M$-291.0M$-76.0M$-40.0M$-98.0M$-107.0M$-49.0M$-14.0M
OPERATING INCOME
Operating income
$14.7B$2.2B$-17.5B$-1.6B$-443.0M$-3.6B$1.7B$-2.2B$433.0M$-303.0M
EBITDA
$3.4B$2.9B$-15.4B$166.0M$1.3B$-1.9B$2.9B$-2.2B$1.6B$497.0M
NON-OPERATING ITEMS
Interest Expense (Non-Operating)
$-270.0M$546.0M$875.0M$920.0M$881.0M$901.0M$891.0M$930.0M$1.0B$1.0B
Intinc
$-1.0B------------------
Net Non-Operating Interest Income/Expense
$-1.0B$-546.0M$-875.0M$-920.0M$-881.0M$-901.0M$-891.0M$991.0M$-1.0B$-1.0B
Gain on Sale of Securities
$631.0M$51.0M$84.0M$39.0M$41.0M$104.0M$31.0M$11.0M$11.0M$34.0M
Other Income/Expense
$121.0M$553.0M$-301.0M$1.0B$835.0M$696.0M$1.0B$-4.9B$1.1B$980.0M
Other Special Charges
$1.2B$-561.0M$304.0M$-959.0M$-822.0M$-834.0M$-1.1B$-966.0M$-1.1B$-981.0M
SPECIAL ITEMS
Restructring And Mn A Income
$-183.0M$245.0M$535.0M$488.0M$199.0M$120.0M$133.0M$146.0M$111.0M$74.0M
Special Income Charges
$279.0M$-900.0M$-17.1B$-3.0B$-1.5B$-4.6B$-850.0M$-2.0B$-700.0M$-1.3B
Impairment of Capital Assets
$-96.0M$900.0M$17.1B$3.0B$139.0M$4.6B--$2.0B$700.0M$1.3B
PRE-TAX INCOME
EBIT
$2.1B$1.4B$-17.5B$-1.7B$-384.0M$-3.5B$1.5B$-2.2B$407.0M$-562.0M
Pre-Tax Income
$2.4B$824.0M$-18.4B$-2.6B$-1.3B$-4.4B$658.0M$-3.2B$-624.0M$-1.3B
INCOME TAX
Tax Provision
$634.0M$521.0M$-1.9B$-195.0M$-278.0M$-168.0M$211.0M$-643.0M$-7.0M$676.0M
NET INCOME
Net Income
$12.9B$329.0M$-16.3B$-2.1B$-999.0M$-4.0B$417.0M$-2.4B$-559.0M$-1.6B
Net Income (Continuing Operations)
$12.9B$329.0M$-16.3B$-2.1B$-999.0M$-4.0B$417.0M$-2.5B$-615.0M$-2.2B
Net Income (Discontinued Operations)
$12.9B$329.0M$-16.3B$-2.1B$-999.0M$-4.0B$417.0M$-2.4B$-559.0M$-1.6B
Net Income (Common Stockholders)
$12.9B$68.0M$-16.5B$-2.4B$-999.0M$92.0M$417.0M$-2.4B$-559.0M$-1.6B
Normalized Income
------$1.5B$1.6B$1.6B------$897.8M
TOTALS
Total Expenses
$-292.0M$15.0B$12.8B$13.3B$10.9B$11.5B$11.2B$12.1B$12.6B$13.2B
SHARE & EPS DATA
Average Shares Outstanding
$855.0M$955.0M$1.0B$1.0K$1.1B$1.1B$1.1B$1.1B$1.1B$1.1B
Average Shares Outstanding (Diluted)
$864.0M$961.0M$1.0B$1.0K$1.1B$1.1B$1.1B$1.1B$1.1B$1.1B
Shares Outstanding
$1.0B$1.1B$1.1B$1.1B$1.1B$1.1B$1.1B$1.1B$1.1B$1.1B
Basic EPS
$1.84$0.07$-16.26$-2.35$-0.91$-3.64$0.38$-2.12$-0.50$-1.45
Basic EPS (Continuing Operations)
--$0.07$-16.26$-2.35$-0.91$-3.64$0.38$-2.12$-0.50$-1.45
Diluted EPS
$1.82$0.07$-16.26$-2.35$-0.91$-3.64$0.38$-2.12$-0.50$-1.45
Diluted EPS (Continuing Operations)
--$0.07$-16.26$-2.35$-0.91$-3.64$0.38$-2.12$-0.50$-1.45
Dividend Per Share
$1.36$1.36$1.36--------------
OTHER METRICS
Accrued Preferred Stock Dividends
$15.0M$261.0M$260.0M$249.0M------------
Acquisition Expense
--$261.0M$105.0M$13.0M------------
Earnings from equity interest
$-121.0M$8.0M$-3.0M$-71.0M$-13.0M$138.0M$9.0M$21.0M$2.0M$1.0M
Earnings From Equity Interest Net Of Tax
$-121.0M$8.0M$-3.0M$-71.0M$-13.0M$138.0M$9.0M$21.0M$2.0M$1.0M
Gain On Sale Of Business
------$67.0M$50.0M$8.0M$51.0M$46.0M$3.0M$15.0M
Gain On Sale Of P P E
------$9.0M$-1.0M$11.0M$7.0M$18.0M$25.0M$2.0M
Minority Interests
$-9.0M$18.0M$184.0M$322.0M$2.0M$109.0M$-39.0M$53.0M$56.0M$320.0M
Net Income Discontinuous Operations
------------------$281.0M
Non Recurring Operation Expense
------$-1.2B$1.2B$60.0M$717.0M$2.1B$1.0B$-495.0M
Other Gain Loss From Disposition Of Discontinued Operations
------------------$281.0M
Other Gand A
$1.2B$1.3B$1.3B$1.3B$1.2B$1.2B$1.1B$1.2B$1.2B$1.2B
Other Impairment Of Capital Assets
$-361.0M$746.0M$3.8B$2.0B$1.6B$1.5B$424.0M$355.0M$350.0M$1.0B
Otherunder Preferred Stock Dividend
$15.0M$261.0M$260.0M$249.0M------------
Preferred Stock Dividends
$15.0M$261.0M$260.0M$249.0M------------
Rent And Landing Fees
$1.2B$164.0M$200.0M$175.0M------------
Selling Expense
$3.5B------------------
Restruct
$-183.0M$245.0M$535.0M$488.0M$199.0M$120.0M$133.0M$146.0M$111.0M$74.0M

Financial data is updated quarterly and may not reflect the most recent earnings.

ABCD
1SymbolPriceChangeVol
2TEVA$19.50+3.3%10.29M
3
4
5
6

Get Teva Pharmaceutical Industries Limited American Depositary Shares Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.